Project Grant F30AA031900

Award Date 1/11/25
Completion Date 7/31/28
Dollars Obligated $82K
Federal Grant Program
93.273
Assistance Type
Project Grant
Place of Performance
New Orleans, LA 70112, USA
Similar Awards
This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), provides $159,056 to The Washington University in St. Louis to investigate the role of a novel dynorphinergic central amygdala-nucleus accumbens circuit in driving binge-like alcohol drinking during persistent pain and protracted fentanyl abstinence. The research aims to elucidate the circuit-level mechanisms underlying the co-occurrence of chronic...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $424,194 Project Grant under the Alcohol Research Programs (CFDA 93.273) to George Washington University (The) to conduct research on the genetic architecture underlying the comorbidity of alcohol use disorder (AUD) and chronic pain (CP). The project aims to: 1) Estimate the shared genetic variance contributing to AUD and CP phenotypes and the unique genetic variance for each, 2) Determine the extent to which AUD-CP...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a 5-year, $2,726,432 research study on co-use of cannabis and prescription opioids among emerging adults in medical settings. The study will enroll emerging adults aged 18-25 who either have no history of cannabis use or have used cannabis in the past month and are prescribed an opioid for acute pain management. Participants will be followed...
The National Institute on Drug Abuse (NIDA) awarded a $137,619 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Washington. The grant, awarded on January 19, 2025, will support research to investigate the role of tetrahydrocannabinol (THC) in mediating pain signaling in the basolateral amygdala (BLA) brain region. The study aims to determine how THC, acting through cannabinoid 1 receptors (CB1R), alters glutamatergic neuronal activity in the BLA...
This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, aims to study the effects of cannabis use on treatment outcomes for adolescents with alcohol use disorder (AUD) and co-occurring psychiatric disorders (CODs) in community-based treatment settings. The $197,262 award will leverage mixed methods, including qualitative interviews, an ecological momentary assessment pilot, and...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $143,784 Project Grant (CFDA 93.273 - Alcohol Research Programs) to Louisiana State University Health Sciences Center New Orleans on July 30, 2024. The grant will support research to investigate the effects of adolescent opioid exposure on alcohol-induced hyperalgesia (increased pain sensitivity) in adult mice. The research aims to test the hypothesis that exposure to opioids during adolescence increases the magnitude of...
This $144,362 Project Grant was awarded on July 23, 2024 by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) federal grant program. The grant supports research to investigate the neural mechanisms underlying the relationship between chronic alcohol exposure and heightened pain sensitivity during alcohol withdrawal. Specifically, the research aims to determine how chronic alcohol exposure impacts the activity of neuropeptide Y...
Under a $368,673 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded on September 25, 2023, Artiam Bio Inc., a minority-owned small disadvantaged biotechnology company, is developing and evaluating second-generation partial inverse agonists targeting the type 1 cannabinoid (CB1) receptor as a potential therapy for alcohol use disorder (AUD). Artiam Bio is conducting preclinical efficacy studies of its lead CB1 receptor partial inverse agonist compound in rat...
This federal Project Grant award, provided by the National Center for Complementary and Integrative Health (NCCIH) under the Research and Training in Complementary and Integrative Health program (CFDA 93.213), will fund research to elucidate how terpenes, naturally occurring compounds in cannabis, can modulate pain hypersensitivity via the endocannabinoid system. The $131,453 award to the University of California, Los Angeles (UCLA) will support in vivo studies using a chronic pain mouse model...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $194,551 Project Grant under the Alcohol Research Programs (CFDA 93.273) to The Medical University of South Carolina. The funding supports research to investigate the effects of adolescent intermittent ethanol exposure on the regulation of a neural pathway involving the prelimbic cortex and ventrolateral periaqueductal gray, and its impact on pain processing and sensitivity. The research aims to elucidate how changes in the...

ALCOHOL-CANNABINOID SYSTEM INTERACTIONS IN THE CONTEXT OF PAIN AND AUD - ABSTRACT ALCOHOL USE DISORDER (AUD) AFFECTS MORE THAN 10% OF THE UNITED STATES POPULATION. AUD IS A PSYCHIATRIC DISORDER CHARACTERIZED BY ESCALATED ALCOHOL DRINKING AND THE EMERGENCE OF PROFOUND NEGATIVE AFFECTIVE STATES, INCLUDING PERSISTENT PAIN. ALCOHOL IS ALSO KNOWN FOR ITS ANALGESIC EFFECTS, ALTHOUGH EXCESSIVE USE FACILITATES PAIN SENSITIVITY (OR HYPERALGESIA) DURING WITHDRAWAL. WHILE CHRONIC PAIN AFFECTS OVER 20% OF THE GLOBAL POPULATION AND CONTRIBUTES TO THE DEVELOPMENT AND SEVERITY OF BOTH PSYCHIATRIC ILLNESS AND AUD, EFFECTIVE PHARMACOLOGICAL TREATMENTS FOR THESE CONDITIONS REMAIN VERY LIMITED. IN RECENT YEARS, MANY PEOPLE HAVE TURNED TO CANNABIS FOR MANAGEMENT OF CHRONIC PAIN AND VARIOUS NEGATIVE EMOTIONAL SYMPTOMS ASSOCIATED WITH MENTAL ILLNESS. HOWEVER, THERE IS A SIGNIFICANT GAP IN KNOWLEDGE REGARDING THE ANALGESIC EFFICACY OF PRIMARY CANNABIS CONSTITUENTS IN THE CONTEXT OF ALCOHOL DEPENDENCE AND HOW USE MAY EITHER MITIGATE OR WORSEN THE RISK OF SUBSTANCE USE DISORDERS. SPECIFICALLY, DELTA-9-TETRAHYDROCANNABINOL (THC), THE MAIN PSYCHOACTIVE COMPONENT OF CANNABIS, MAY OFFER A PROMISING AVENUE FOR PAIN MANAGEMENT, A COMMON CAUSE OF EXCESSIVE DRINKING IN INDIVIDUALS WITH AUD. FROM A NEUROBIOLOGICAL PERSPECTIVE, THE EXTENDED AMYGDALA (EA) PLAYS AN IMPORTANT ROLE IN STRESS- AND PAIN-RELATED COMPONENTS OF AUD AND IS A SITE WHERE THE ENDOCANNABINOID (ECB) SYSTEM APPEARS CRITICAL FOR MODULATING THE REINFORCING EFFECTS OF ETHANOL AND TRANSITION TO DEPENDENCE. OUR PREVIOUS PRECLINICAL WORK HAS SHOWN A FUNCTIONAL ROLE FOR THE CENTRAL AMYGDALA (CEA), A CONSTITUENT OF THE EA, AS A KEY BRAIN REGION UNDERLYING HYPERALGESIA AND ESCALATION OF ALCOHOL DRINKING IN ALCOHOL-DEPENDENT ANIMAL MODELS. OUR PRELIMINARY DATA INDICATE AN ECB SYSTEM DYSREGULATION GENERATED BY CHRONIC ALCOHOL EXPOSURE, WHICH MAY PROMOTE THE USE OF ALCOHOL AND IMPLY THE THERAPEUTIC EFFICACY OF CANNABIS/THC IN INDIVIDUALS SUFFERING FROM AUD AND AUD-RELATED HYPERALGESIA. THE MAIN RESEARCH OBJECTIVE OF THE CURRENT PROPOSAL IS TO INVESTIGATE THE INTRICATE INTERPLAY BETWEEN THE ENDOCANNABINOID SYSTEM, PAIN, AND ALCOHOL USE. THE STUDIES OUTLINED IN THIS F30 TRAINING PROPOSAL INCORPORATE BOTH ANIMAL MODELING AND CLINICAL INVESTIGATION TO EXAMINE THE PREDICTIONS THAT: 1) DELTA-9-THC ADMINISTRATION ALLEVIATES HYPERALGESIA AND REDUCES ESCALATED ALCOHOL SELF-ADMINISTRATION IN ALCOHOL-DEPENDENT MALE AND FEMALE RATS, AND 2) INCREASED CANNABIS USE IS ASSOCIATED WITH OVERALL REDUCTIONS IN PAIN SYMPTOMS AND AT-RISK ALCOHOL USE IN MEN AND WOMEN. THIS PROPOSAL WILL PROVIDE A PROMISING FUTURE PHYSICIAN-SCIENTIST WITH VITAL RESEARCH TRAINING TO BECOME AN INDEPENDENT SCIENTIST IN THE FIELD OF ALCOHOL AND CLINICAL NEUROSCIENCE RESEARCH.

Posted 7/11/24